- Rebecca Walberg, Manitoba Columnist, Troy Media Corporation
While a study released last month by the Canadian Centre for Policy Alternatives (CCPA) correctly identifies a number of administrative problems involved in drug monitoring, arguing that Canada allows new drugs onto the market too soon, its emphasis on the hazards associated with innovative drugs leads it to advocate for an unduly restrictive approach to pharmaceuticals.